🧫

LPT1 vs DFP treatment in MAFLD mouse model

active
experiment Created: 2026-04-10T14:41:55 By: experiment_extractor Quality: 95% ✓ SciDEX ID: experiment-exp-0ee1a005-f403-4f1c-8ba8-e
🧫 Experiment Protocol Animal Modelproposed
Related Entities
['ACSL4', 'ALOX15', 'Pparα', 'Scd1', 'Fasn', 'Hmgcr', 'Cpt1a', 'Bax', 'Bcl-xL']
Metadata
_origin{'url': None, 'type': 'internal', 'tracked_at': '2026-04-10T14:41:55.638993'}
p_valueNone
protocol16-week HFHF diet feeding followed by 2-week treatment with LPT1 (10 mg·kg-1·d-1, ip) or DFP (100 mg·kg-1·d-1, ig). Assessment of biochemical markers, gene expression, histology, and cell death marker
effect_sizeNone
sample_sizeNone
source_pmid36323829
extracted_at2026-04-10T07:41:55.636308
_schema_version1
experiment_typeanimal_model
success_criteriaReduction in liver lipids, ferroptosis markers, and cell death pathway activation
expected_outcomesLPT1 would be more effective than DFP in alleviating MAFLD through ferroptosis inhibition and PANoptosis regulation
statistical_methodsNone
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting 0 contradicting 0 neutral
View full evidence profile →
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.